K
Keros Therapeutics, Inc. (KROS)
10.61
0.00 (0.00%)
Get all premium features to the best stock analysis tool
10.61
0.00 (0.00%)
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Name | Position |
|---|---|
| Dr. Jasbir S. Seehra Ph.D. | President, CEO & Director |
| Dr. Lorena Lerner Ph.D. | Chief Scientific Officer |
| Mr. Keith C. Regnante MBA | Chief Financial Officer |
| Ms. Esther Cho J.D. | Chief Legal Officer & Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-03-09 | 8-K | kros-20260309.htm |
| 2026-03-04 | 8-K | kros-20260304.htm |
| 2026-01-09 | 8-K | kros-20260109.htm |
| 2025-11-20 | SC TO-I/A | tm2531864d1_sctoia.htm |
| 2025-11-19 | SC TO-I/A | tm2531400d1_sctoia.htm |
| 2025-11-05 | 10-Q | kros-20250930.htm |
| 2025-10-20 | SC TO-I | tm2528628-1_sctoi.htm |
| 2025-10-15 | SC TO-C | tm2528773d2_sctoc.htm |
| 2025-09-08 | 8-K | kros-20250908.htm |
| 2025-08-28 | 8-K | kros-20250828.htm |